未经证实:肺淋巴上皮瘤样癌(LELC)表现出独特的免疫微环境,包括高PD-L1表达和丰富的浸润免疫细胞。然而,PD-1/PD-L1抑制剂在LELC患者中的可用性仍未确定.
UNASSIGNED:共36例PD-1/PD-L1抑制剂治疗的肺LELC,包括来自我们研究所的10例病例和来自文献的26例病例。采用Kaplan-Meier法和log-rank检验分析接受免疫治疗的LELC患者的生存结果。并进一步检查了与免疫治疗反应相关的因素。
未经授权:在我们研究所的10名患者中,中位年龄为53.5岁,肾上腺和远处淋巴结是最常见的转移部位,8例患者中有4例(50%)PD-L1TPS≥50%。我们研究所和文献中患者的中位无进展生存期和总生存期分别为11.6和27.3个月,17.2个月,没有达到,分别。在所有36名患者中,客观有效率高达57.6%。PD-L1表达较高的患者更有可能有肿瘤反应,但PD-L1表达与生存时间的相关性仍有待确定。
UASSIGNED:PD-1/PD-L1抑制剂在肺部LELC患者中在回顾性队列中表现出了有希望的疗效,并且值得在一线环境下管理的前瞻性研究中进一步验证。
Pulmonary lymphoepithelioma-like carcinoma (LELC) exhibits a unique immune microenvironment, including high PD-L1 expression and abundant infiltrating-immune cells. However, the availability of PD-1/PD-L1 inhibitors in patients with LELC is still not determined.
A total of 36 cases of pulmonary LELC treated with PD-1/PD-L1 inhibitors were reviewed, including 10 cases from our institute and 26 cases included from the literature. The Kaplan-Meier method and log-rank test were utilized to analyze the survival outcomes of LELC patients receiving immunotherapy, and the factors related to immunotherapy response were further examined.
Of the 10 patients from our institute, the median age was 53.5 years, adrenal glands and distant lymph nodes were the most common metastatic sites, and 4 of 8 (50%) patients had a PD-L1 TPS ≥50%. The median progression-free survival and overall survival in patients from our institute and from the literature were 11.6 and 27.3 months, 17.2 months and not reached, respectively. In all 36 patients, the objective response rate was as high as 57.6%. Patients with higher PD-L1 expression were more likely to have a tumor response, but the association of PD-L1 expression with survival time remains to be determined.
PD-1/PD-L1 inhibitors in patients with pulmonary LELC demonstrated a promising efficacy in retrospective cohorts, and deserve further validation in prospective studies administrating in front-line setting.